Disease Assessment After Treatment

After first-line treatment and upon hematologic recovery, bone marrow aspirate and biopsy are performed to evaluate measurable residual disease (MRD) status and remission status. For patients younger than 60 years of age, post-remission therapy is also based on cytogenetics and/or molecular abnormalities.

  • Timing of post-induction bone marrow assessment varies by regimen but is recommended 14-21 days* post induction, and if patient is ambiguous for hypoplasia, consider repeating after 5-7 days to determine blood count recovery and remission status before continuing treatment

Results of follow-up bone marrow aspirate, biopsy, and MRD/molecular testing guide next steps in AML treatment.

*21-28 days for patients with physiologic age <60 years after high-dose induction.

Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 22, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.